Medicago is building a 646,000-sf vaccine manufacturing complex in Quebec City, Canada. Designed by NFOE, the facility will support the production of approximately 50 million doses of recombinant quadrivalent influenza vaccine per year. The project has a construction cost of CAD$143 million and is expected to be fully operational in 2023.
Medicago is currently developing a vaccine for SARS-CoV-2 which has successfully induced a positive antibody response in mouse models. Human clinical trials are expected to begin in summer of 2020.
The company uses a proprietary plant-based technology (instead of live viruses or animal products) to create protein-based therapeutics that utilize Virus-Like Particles (VLPs) to trigger a human immune response. Rapid, versatile, and scalable, the proprietary technology enables a clinical-grade vaccine candidate to be developed only weeks after obtaining access to the genetic sequence of a virus. Based in Quebec City, Medicago also has a manufacturing campus in Durham, N.C.